IMR Press / EJGO / Volume 34 / Issue 5 / pii/1630906443632-732754634

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/ TGCU Intergroup surveillance
Show Less
1 Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago
2 Department of Gynecology, Hyogo Cancer Center, Akashi
3 Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima
4 Department of Gynecology, National Hospital Organization Shikoku Cancer Center, Matsuyama
5 Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center, Kure
6 Department of Gynecology, Miyagi Cancer Center, Natori
7 Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima
8 Department of Obstetrics and Gynecology, Yamagata University, Yamagata
9 Department of Obstetrics and Gynecology, Iwate Medical University, Morioka
10 Department of Cancer Center, Tottori University Hospital, Yonago (Japan)
Eur. J. Gynaecol. Oncol. 2013, 34(5), 425–428;
Published: 10 October 2013

Purpose: The authors conducted this retrospective study to evaluate the efficacy of radiotherapy (RT) for high-risk patients with adenocarcinoma (AC) compared with chemotherapy (CT) after radical hysterectomy. Materials and Methods: There were 263 patients with AC and 58 with adenosquamous cell carcinoma (ASCC). Of these 321 patients, 151 received adjuvant treatment. Of these 151 patients, 69 received radiotherapy (RT) alone, including concurrent chemoradiotherapy (CCRT) with weekly cisdiamminedichloroplatinum (CDDP), 64 patients received CT alone, and 18 patients received concomitant RT and CT (RT + CT). Results: The five-year overall survival (OS) was 70.9% for patients receiving RT, 79.2% for CT, and 66.2% for RT + CT. Adjuvant treatment did not affect the incidence or the pattern of recurrence. The incidence of lymph node involvement was 9.0% in Stage Ib1, 23.9% in Stage Ib2, 30.8% in Stage IIa, and 41.2% in Stage IIb. Conclusions: Adjuvant CT may be effective for high-risk patients with cervical adenocarcinoma.
Uterine cervix
Back to top